Luma Group is a New York–based multistage biotechnology firm combining scientific insight with computation. Its differentiator is LABI, a proprietary AI system used to analyse data, validate breakthroughs and assess potential during diligence. The team backs first-principles science with clear translational paths across therapeutics, diagnostics and devices, and publishes original research including whitepapers on regulatory reform in areas such as osteoporosis. Portfolio includes Altos Labs, Arsenal Biosciences, Rome Therapeutics, Character Biosciences, Aeovian Pharmaceuticals, Curve Biosciences, Integrated Biosciences, Coultreon Biopharma and SciThera, with a vaccine company acquired by Eli Lilly in 2026. Team and AUM not publicly disclosed.